Home About us Contact
|
Home About us Contact | ||
|
|
||
Novel Drug Targets (novel + drug_target)
Selected AbstractsObovatol attenuates microglia-mediated neuroinflammation by modulating redox regulationBRITISH JOURNAL OF PHARMACOLOGY, Issue 8 2010Jiyeon Ock Background and purpose:, Obovatol isolated from the medicinal herb Magnolia obovata exhibits a variety of biological activities. Here, the effect of obovatol and its mechanism of action on microglial activation, neuroinflammation and neurodegeneration were investigated. Experimental approach:, In microglial BV-2 cells stimulated with lipopolysaccharide (LPS), we measured nitric oxide (NO) and cytokine production, and activation of intracellular signalling pathways by reverse transcription-polymerase chain reaction and Western blots. Cell death was assayed in co-cultures of activated microglia (with bacterial LPS) and neurons and in LPS-induced neuroinflammation in mice in vivo. Key results:, Obovatol inhibited microglial NO production with an IC50 value of 10 µM. Obovatol also inhibited microglial expression of proinflammatory cytokines and inducible nitric-oxide synthase, which was accompanied by the inhibition of multiple signalling pathways such as nuclear factor kappa B, signal transducers and activators of transcription 1, and mitogen-activated protein kinases. In addition, obovatol protected cultured neurons from microglial toxicity and inhibited neuroinflammation in mice in vivo. One molecular target of obovatol in microglia was peroxiredoxin 2 (Prx2), identified by affinity chromatography and mass spectrometry. Obovatol enhanced the reactive oxygen species (ROS)-scavenging activity of Prx2 in vitro, thereby suppressing proinflammatory signalling pathways of microglia where ROS plays an important role. Conclusions and implications:, Obovatol is not only a useful chemical tool that can be used to investigate microglial signalling, but also a promising drug candidate against neuroinflammatory diseases. Furthermore, our results indicate that Prx2 is a novel drug target that can be exploited for the therapeutic modulation of neuroinflammatory signalling. [source] Monogenic migraine syndromes highlight novel drug targetsDRUG DEVELOPMENT RESEARCH, Issue 7 2007J. Jay Gargus Abstract In the post-genomic era, the paradigm for drug discovery has changed, as every gene may become a potential target. Genetic diseases provide a special window into gene target selection. This approach is being applied to migraine making use of the genes and mutations causing familial hemiplegic migraine (FHM). FHM is caused by missense mutations in CACNA1A, altering a neuronal P/Q Ca2+ channel, in ATP1A2, altering ,2 Na,K-ATPase, and in SCN1A, altering a neuronal sodium channel. These genes provide insights into migraine pathogenesis that likely extend to other forms of migraine as well. Since the three FHM genes are only co-expressed in neurons, FHM is a neuronal, not a vascular, disease and because they all encode ion transport proteins, FHM is a neuronal channelopathy,meaning meta-stable neuronal hyperexcitability is the substrate of migraine, much as it is for genetic epilepsy syndromes. This similarity is reinforced, since different mutations of all three FHM genes can produce seizure syndromes. This has implications for drug discovery in that seizure medications already known to modulate the FHM channel mechanisms warrant more targeted development, and that drugs targeted to vascular headaches, such as the historically effective triptans, or experimental botulinum toxin, may well work by similar nonvascular mechanisms. Finally, in model neurogenetic systems such as Caenorhabditis elegans, the FHM genes also provide both a comprehensive means to discover all genes involved in their signaling pathway,genes potentially involved in common forms of the disease, and an in vivo whole animal means to screen rapidly for novel therapeutics. Drug Dev Res 68:432,440, 2007. © 2008 Wiley-Liss, Inc. [source] Use of proteomics for the identification of novel drug targets in brain diseasesJOURNAL OF NEUROCHEMISTRY, Issue 2 2007Jose A. Morón Abstract In spite of the rapid advances in the development of the new proteomic technologies, there are, to date, relatively fewer studies aiming to explore the neuronal proteome. One of the reasons is the complexity of the brain, which presents high cellular heterogeneity and a unique subcellular compartmentalization. Therefore, tissue fractionation of the brain to enrich proteins of interest will reduce the complexity of the proteomics approach leading to the production of manageable and meaningful results. In this review, general considerations and strategies of proteomics, the advantages and challenges to exploring the neuronal proteome are described and summarized. In addition, this article presents an overview of recent advances of proteomic technologies and shows that proteomics can serve as a valuable tool to globally explore the changes in brain proteome during various disease states. Understanding the molecular basis of brain function will be extremely useful in identifying novel targets for the treatment of brain diseases. [source] A new high-content model system for studies of gastrointestinal transit: the zebrafishNEUROGASTROENTEROLOGY & MOTILITY, Issue 3 2009A. Rich Abstract, The zebrafish gastrointestinal (GI) tract displays an anatomy and cellular architecture that is similar to the human GI tract, with concentric layers of inner epithelia, connective tissue, circular muscle and outer longitudinal muscle layers. Propulsion of luminal content results from the integrated activity of smooth muscle cells, enteric neurons and the interstitial cells of Cajal (ICC). Zebrafish larvae are transparent and propagating contractions in the entire GI tract are easily visualized. A new moderate-throughput zebrafish-based GI transit assay is described in this issue of Neurogastroenterology and Motility. This assay utilizes intact zebrafish larvae which contain essential regulatory elements (ICC and enteric neurons). Forward genetic analysis, which identifies genes underlying specific phenotypes, is possible using the zebrafish system. The zebrafish model system compliments existing models for studies of GI motility and will contribute to the understanding of the regulation of GI motility, and to identification of novel drug targets. [source] "Click Peptides",Chemical Biology-Oriented Synthesis of Alzheimer's Disease-Related Amyloid , Peptide (A,) Analogues Based on the "O- Acyl Isopeptide Method"CHEMBIOCHEM, Issue 10 2006Youhei Sohma Abstract A clear understanding of the pathological mechanism of amyloid , peptide (A,) 1,42, a currently unexplained process, would be of great significance for the discovery of novel drug targets for Alzheimer's disease (AD) therapy. To date, though, the elucidation of these A,1,42 dynamic events has been a difficult issue because of uncontrolled polymerization, which also poses a significant obstacle in establishing experimental systems with which to clarify the pathological function of A,1,42. We have recently developed chemical biology-oriented pH- or phototriggered "click peptide" isoform precursors of A,1,42, based on the "O -acyl isopeptide method", in which a native amide bond at a hydroxyamino acid residue, such as Ser, is isomerized to an ester bond, the target peptide subsequently being generated by an O,N intramolecular acyl migration reaction. These click peptide precursors did not exhibit any self-assembling character under physiological conditions, thanks to the presence of the one single ester bond, and were able to undergo migration to give the target A,1,42 in a quick and easy, one-way (so-called "click")conversion reaction. The use of click peptides could be a useful strategy to investigate the biological functions of A,1,42 in AD through inducible activation of A,1,42 self-assembly. [source] | ||||||||||